Has Osimertinib been launched in China?

Osimertinib is a third-generation EGFR tyrosine kinase inhibitor developed by AstraZeneca in the UK.

Is Osimertinib available in China?

has been launched in China under the trade name Tagrisso, providing an important treatment option for domestic patients with EGFR mutated non-small cell lung cancer.

In addition to the original drug (produced by AstraZeneca), there are also multiple versions of generic drugs on the market, providing patients with choices at different price levels.

Osimertinib has been successfully included in China’s national medical insurance drug catalog. Patients who meet the indications can enjoy medical insurance reimbursement when using it in outpatient or inpatient settings, significantly reducing the economic burden of long-term treatment. The specific reimbursement ratio varies according to local medical insurance policies, so you need to consult the local medical insurance department or hospital.

Patients can purchase it at major hospital pharmacies or regular chain pharmacies with a doctor’s prescription. When purchasing through an online drug purchasing platform, be sure to choose a formal platform with drug sales qualifications and verify the authenticity of the drug.

Osimertinib usage and dosage

1. Standard dosage regimen

(1). Recommended dosage: 80 mg (1 tablet) each time, once a day.

(2) How to take: Take orally, with food or on an empty stomach, no restrictions. It is recommended to take the medicine at a fixed time every day to maintain a stable blood concentration.

2. Handling special situations

(1). Missed dose: If you forget to take the medicine, you should not take it again. You only need to take one tablet as usual at the next scheduled medication time. Never take a double dose at one time.

(2) Difficulty swallowing: If the patient cannot swallow the whole tablet, the tablet can be put into 60 ml of non-carbonated beverage (such as water), stir and dispersed into small pieces, then drink immediately, then rinse the cup with water and take it. Do not crush or heat tablets. If administration via nasogastric tube is required, follow specific operating instructions.

3. Duration of treatment

(1) Adjuvant treatment: usually continuous treatment for up to 3 years, or until disease relapses or intolerable toxicity occurs.

(2) Treatment of metastatic lung cancer: Medication should be continued until disease progression or intolerable toxicity occurs.

4. Dose adjustment

If the patient experiences serious adverse reactions, the dose should be suspended, reduced (such as reduced to 40 mg/day) or permanently discontinued under the guidance of a doctor. It is strictly forbidden to adjust the dose by yourself.